Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 15;23(1):36.
doi: 10.1186/s13063-021-05970-7.

Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial

Sua Jo  1 , Hyeyeon Moon  1 , Kyungil Park  2   3 , Chang-Bae Sohn  4 , Jeonghwan Kim  5 , Yong-Seop Kwon  6 , Su Hong Kim  7
Affiliations

Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial

Sua Jo et al. Trials. .

Abstract

Background: Dilated cardiomyopathy (DCMP) is characterized by ventricular chamber enlargement and systolic dysfunction which may cause heart failure. Patients with DCMP have overactivation of the renin-angiotensin-aldosterone systems, which can also adversely affect myocardial metabolism in heart failure. The impairment of myocardial metabolism can contribute to the progression of left ventricular remodeling and contractile dysfunction in heart failure. Although angiotensin II receptor blockers (ARBs) have been used to treat patients with DCMP, there has been no direct comparison of the efficacy of these agents. The objective of this study is to compare the effects of olmesartan and valsartan on myocardial metabolism in patients with DCMP.

Methods/design: The OVOID study (a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy) is designed as a non-blinded, open-label, parallel-group, prospective, randomized, controlled, multicenter clinical trial. A total of 40 DCMP patients aged between 20 and 85 years will be randomly allocated into the olmesartan or the valsartan group. 18F-fluoro-2-deoxyglucose (FDG) cardiac positron emission tomography (PET) will be performed at baseline and six months after receiving the study agent. The primary endpoint is myocardial glucose consumption per square meter, measured using 18F-FDG PET 6 months after receiving the study agent.

Discussion: The purpose of this trial is to compare the efficacy between olmesartan and valsartan in improving myocardial metabolism in DCMP patients. This will be the first randomized comparative study investigating the differential effects of ARBs on heart failure.

Trial registration: ClinicalTrials.gov NCT04174456 . Registered on 18 November 2019.

Keywords: Myocardial metabolism; Olmesartan; Positron emission tomography; Valsartan.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study design. FDG, fluoro-2-deoxyglucose; PET, positron emission tomography
See this image and copyright information in PMC

References

    1. Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol. 2016;67(25):2996–3010. doi: 10.1016/j.jacc.2016.03.590. - DOI - PubMed
    1. Katz AM. Mechanisms and abnormalities of contractility and relaxation in the failing heart. Cardiologia. 1993;38(12 Suppl 1):39–43. - PubMed
    1. Eichhorn EJ, Hesch CN, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24(5):1310–1320. doi: 10.1016/0735-1097(94)90114-7. - DOI - PubMed
    1. Kjekshus JK, Mjos OD. Effect of inhibition of lipolysis on myocardial oxygen consumption in the presence of isoproterenol. J Clin Invest. 1972;51(7):1767–1776. doi: 10.1172/JCI106978. - DOI - PMC - PubMed
    1. Mori J, Zhang L, Oudit GY, Lopaschuk GD. Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure. J Mol Cell Cardiol. 2013;63:98–106. doi: 10.1016/j.yjmcc.2013.07.010. - DOI - PubMed

Publication types

Associated data